And to date, we see this sort of operating as business usual, the type of information requests that we’re getting ... Are now docs being a lot more cautious in prescribing this in non ambulatory ...

Meanwhile, blockbuster eye drug Eylea grew nearly 5% to €815 million thanks to a new high-dose formulation that reduces the number of injections needed into the eye. "We know the Xarelto ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

By using this site, you consent to our User Agreement and agree that your clicks, interactions, and personal information may be collected, recorded, and/or stored by us and social media and other ...

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and ...

Brekiya consists of dihydroergotamine mesylate, an ergotamine derivative, in a single-dose autoinjector for subcutaneous administration.

All 15 Women's WorldTour teams will be heading to the Basque Country to take on the race this year, even if the start list has yet to be finalised. The riders will take on 377km of hilly roads ...

In April this year, the company also submitted an application for a third indication of Eylea™ 8 mg with the European Medicines Agency. It is likely that the medicine used to treat patients with ...

Regeneron's first-quarter results miss on lower Eylea demand Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea ...

This makes Brekiya the first DHE autoinjector for treating these conditions. The autoinjector offers potential pain relief ...

The US Food and Drug Administration (FDA) has accepted BioCryst Pharmaceuticals’ new drug application (NDA) for Orladeyo ...

Regeneron's first-quarter results miss on lower Eylea demand Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea ...